The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

The researchers obtained data from 601 randomized controlled trials. They found that treatment with SGLT2 inhibitors, GLP-1 receptor agonists or dipeptidyl peptidase 4 (DPP-4) inhibitors lowered ...

A latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...

UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have ... including sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors. Compared to usual care, GLP-1RA use was linked ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

As drugs like Ozempic and Mounjaro continue to skyrocket in usage, doctors are encountering more cases linking them to ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors and GLP-1 receptor agonists were associated with fewer exacerbations of COPD in adults with type 2 ...

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb. 3 in ...